ESR1 and breast cancer: Knockdown of PTK7 mediated by siRNA, treatment with an anti-PTK7 polyclonal antibody, or overexpression of a kinase domain-deleted PTK7 mutant have been shown to decrease the motility and invasiveness of ER-positive Hs578T BC cells [22].